Mechanism of action of a novel human ether-a-go-go-related gene channel activator

被引:97
作者
Casis, O
Olesen, SP
Sanguinetti, MC [1 ]
机构
[1] Univ Utah, Nora Eccles Harrison Cardiovasc Res & Training In, Salt Lake City, UT 84112 USA
[2] Univ Utah, Dept Physiol, Salt Lake City, UT USA
[3] Univ Basque Country, Dept Fisiol, Bilbao, Spain
[4] Univ Copenhagen, Dept Physiol, Danish Arrhythmia Res Ctr, Copenhagen, Denmark
[5] Copenhagen & NeuroSearch, Ballerup, Denmark
关键词
D O I
10.1124/mol.105.019943
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
1,3-Bis-(2-hydroxy-5-trifluoromethyl-phenyl)-urea (NS1643) is a newly discovered activator of human ether-a-go-go-related gene (hERG) K+ channels. Here, we characterize the effects of this compound on cloned hERG channels heterologously expressed in Xenopus laevis oocytes. When assessed with 2-s depolarizations, NS1643 enhanced the magnitude of wild-type hERG current in a concentration- and voltage-dependent manner with an EC50 of 10.4 mu M at -10 mV. The fully activated current-voltage relationship revealed that the drug increased outward but not inward currents, consistent with altered inactivation gating. NS1643 shifted the voltage dependence of inactivation by +21 mV at 10 mu M and mu 35 mV at 30 mu M, but it did not alter the voltage dependence of activation of hERG channels. The effects of the drug on three inactivation- deficient hERG mutant channels (S620T, S631A, and G628C/S631C) were determined. In the absence of channel inactivation, NS1643 did not enhance hERG current magnitude. The agonist activity of NS1643 was facilitated by mutations (F656 to Val, Met, or Thr) that are known to greatly attenuate channel inhibition by hERG blockers. We conclude that NS1643 is a partial agonist of hERG channels and that the mechanism of activation is reduced channel inactivation.
引用
收藏
页码:658 / 665
页数:8
相关论文
共 31 条
[1]   Physicochemical features of the hERG channel drug binding site [J].
Fernandez, D ;
Ghanta, A ;
Kauffman, GW ;
Sanguinetti, MC .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2004, 279 (11) :10120-10127
[2]   Activation of human ether-a-go-go-related gene potassium channels by the diphenylurea 1,3-bis-(2-hydroxy-5-trifluoromethyl-phenyl)-urea (NS1643) [J].
Hansen, RS ;
Diness, TG ;
Christ, T ;
Demnitz, J ;
Ravens, U ;
Olesen, SP ;
Grunnet, M .
MOLECULAR PHARMACOLOGY, 2006, 69 (01) :266-277
[3]   The potential for QT prolongation and proarrhythmia by non-antiarrhythmic drugs: clinical and regulatory implications - Report on a Policy Conference of the European Society of cardiology [J].
Haverkamp, W ;
Breithardt, G ;
Camm, AJ ;
Janse, MJ ;
Rosen, MR ;
Antzelevitch, C ;
Escande, D ;
Franz, M ;
Malik, M ;
Moss, A ;
Shah, R .
EUROPEAN HEART JOURNAL, 2000, 21 (15) :1216-1231
[4]   Suppression of electrical alternans by overexpression of HERG in canine ventricular myocytes [J].
Hua, F ;
Johns, DC ;
Gilmour, RF .
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY, 2004, 286 (06) :H2342-H2352
[5]   Contribution of IKr to rate-dependent action potential dynamics in canine endocardium [J].
Hua, F ;
Gilmour, RF .
CIRCULATION RESEARCH, 2004, 94 (06) :810-819
[6]   Discovery of a small molecule activator of the human ether-a-go-go-related gene (HERG) cardiac K+ channel [J].
Kang, JS ;
Chen, XL ;
Wang, HG ;
Ji, JZ ;
Cheng, H ;
Incardona, J ;
Reynolds, W ;
Viviani, F ;
Tabart, M ;
Rampe, D .
MOLECULAR PHARMACOLOGY, 2005, 67 (03) :827-836
[7]   Molecular and cellular mechanisms of cardiac arrhythmias [J].
Keating, MT ;
Sanguinetti, MC .
CELL, 2001, 104 (04) :569-580
[8]   Potassium channel openers as potential therapeutic weapons in ion channel disease [J].
Lawson, K .
KIDNEY INTERNATIONAL, 2000, 57 (03) :838-845
[9]  
Lees-Miller JP, 2000, MOL PHARMACOL, V57, P367
[10]   TORSADES-DE-POINTES - ATYPICAL RHYTHM, ATYPICAL TREATMENT [J].
MARTINEZ, R .
ANNALS OF EMERGENCY MEDICINE, 1987, 16 (08) :878-884